share_log

广济药业:因涉嫌信披违法违规 遭证监会立案

Hubei Guangji Pharmaceutical: Investigated by the China Securities Regulatory Commission for suspected illegal disclosure and violations.

Breakings ·  Oct 25 17:05

Hubei Guangji Pharmaceutical announced on the evening of October 25 that the company has recently received a "Notice of Filing" issued by the China Securities Regulatory Commission. Due to suspected violations of information disclosure laws and regulations, the China Securities Regulatory Commission has decided to file a case against the company. Currently, all business operations of the company are being carried out normally.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment